Compare EQBK & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | CADL |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2015 | 2021 |
| Metric | EQBK | CADL |
|---|---|---|
| Price | $48.68 | $11.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $51.33 | $19.00 |
| AVG Volume (30 Days) | 73.7K | ★ 1.1M |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ 2.06 | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | $74.58 | N/A |
| Revenue Next Year | $5.11 | N/A |
| P/E Ratio | $23.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.60 | $4.35 |
| 52 Week High | $52.27 | $14.00 |
| Indicator | EQBK | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 46.11 |
| Support Level | $48.53 | $9.40 |
| Resistance Level | $51.93 | $14.00 |
| Average True Range (ATR) | 1.05 | 0.76 |
| MACD | -0.15 | -0.09 |
| Stochastic Oscillator | 31.06 | 44.47 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.